# US 2016/0256436 A1 · Use of equol for treating androgen mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256436 A1
- Document ID: US20160256436A1
- Status: Published application
- Kind: A1
- Application number: 15/065,344
- Filed: 2016-03-09
- Published: 2016-09-08
- Earliest claimed: 2002-10-29
- Assignees: Bringham Young University; Colorado State University Research Foundation
- Inventors: Edwin Douglas Lephart; Trent D. Lund; Robert J. Handa
- Web page: https://patentgrep.com/patent/US20160256436A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 5/24: of the sex hormones
- A61P 5/26: Androgens
- A61P 5/28: Antiandrogens
- A61P 5/30: Oestrogens
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 13/08: of the prostate
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/12: for climacteric disorders
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 7/00: Preparations for affecting hair growth
- A61Q 19/08: Anti-ageing preparations
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of modulating androgen hormone action to ameliorate or enhance at least one condition of the skin or hair of a subject, comprising administering a composition comprising a racemic equol, wherein the racemic equol binds free 5α-dihydrotestosterone and inhibits its binding with the androgen receptor.

### Claim 24 (depends on 23)

The method of claim 23, wherein ameliorating or enhancing at least one condition of the skin or hair of a subject comprises at least one of:
a) enhancing skin integrity,
b) ameliorating or diminishing acne,
c) enhancing anti-photo-aging and skin anti-aging,
d) boosting extracellular matrix proteins, or
e) diminishing scalp hair loss or enhancing the retention of scalp hair (in male or female pattern baldness).

### Claim 25 (depends on 23)

The method of claim 23, wherein the composition is an oral composition comprising a dose sufficient to produce a concentration of the racemic equol in the bloodstream of the subject of at least about 0.2 mg equol per kg weight of the subject.

### Claim 26 (depends on 23)

The method of claim 23, wherein the composition is a topical composition comprising from about 0.1% to about 10% racemic equol.

### Claim 27 (depends on 23)

The method of claim 23, wherein the composition is a topical or subdermal composition comprising from about 0.1% to about 10% for diminishing scalp hair loss or enhancing the retention of scalp hair.

### Claim 28 (depends on 23)

The method of claim 23, wherein the composition further comprises a pharmaceutical active or an excipient.

### Claim 29 (depends on 23)

The method of claim 23, wherein the administering is topically, transdermally, or subdermally.

### Claim 30 (depends on 23)

The method of claim 23, wherein the composition is in a delayed or sustained release formulation.

### Claim 31 (depends on 23)

The method of claim 23, wherein the administering is via a lotion, a spray solution, a foam solution, a pad, a bandage, or a transdermal patch.

### Claim 32

A method of modulating estrogenic hormone action to ameliorate or enhance at least one condition of the skin or hair of a subject, comprising administering a composition comprising a racemic equol, wherein the racemic equol binds estrogen receptor.

### Claim 33 (depends on 32)

The method of claim 32, wherein ameliorating or enhancing at least one condition of the skin or hair of a subject comprises at least one of:
a) enhancing skin integrity,
b) ameliorating or diminishing acne,
c) enhancing anti-photo-aging and skin anti-aging,
d) boosting extracellular matrix proteins, or
e) diminishing scalp hair loss or enhancing the retention of scalp hair (in male or female pattern baldness).

### Claim 34 (depends on 32)

The method of claim 32, wherein the composition is an oral composition comprising a dose sufficient to produce a concentration of the racemic equol in the bloodstream of the subject of at least about 0.2 mg equol per kg weight of the subject.

### Claim 35 (depends on 32)

The method of claim 32, wherein the composition is a topical composition comprising from about 0.1% to about 10% racemic equol.

### Claim 36 (depends on 32)

The method of claim 32, wherein the composition is a topical or subdermal composition comprising from about 0.1% to about 10% for diminishing scalp hair loss or enhancing the retention of scalp hair.

### Claim 37 (depends on 32)

The method of claim 32, wherein the composition further comprises a pharmaceutical active or an excipient.

### Claim 38 (depends on 32)

The method of claim 32, wherein the administering is topically, transdermally, or subdermally.

### Claim 39 (depends on 32)

The method of claim 32, wherein the composition is in a delayed or sustained release formulation.

### Claim 40 (depends on 32)

The method of claim 32, wherein the administering is via a lotion, a spray solution, a foam solution, a pad, a bandage, or a transdermal patch.
